Groundbreaking Research Illuminates Dietary Risks in CPT2 Deficiency
A new study published in the August 2026 issue of Molecular Genetics and Metabolism demonstrates that high dietary fat intake leads to significant muscle structural breakdown, mitochondrial dysfunction, and reduced contractile force in the absence of carnitine palmitoyltransferase 2 (CPT2). The research, led by Andrea S. Pereyra, Filip Jevtovic, Adam J. Amorese, Chien-Te Lin, P. Darrell Neufer, Espen E. Spangenburg, and Jessica M. Ellis, used a mouse model with muscle-specific CPT2 deletion to explore these effects. The full paper is accessible at the original publication.
This work provides critical insights into how dietary choices can exacerbate underlying metabolic vulnerabilities in fatty acid oxidation disorders. Skeletal muscle relies heavily on fatty acid oxidation for energy, especially at rest, making disruptions in this pathway particularly impactful for physical function and overall health.
Understanding CPT2 and Fatty Acid Oxidation Disorders
Carnitine palmitoyltransferase 2, or CPT2, plays an essential role in the carnitine shuttle system that transports long-chain fatty acids into mitochondria for beta-oxidation and energy production. Without functional CPT2, long-chain fatty acids cannot efficiently enter the mitochondrial matrix, leading to energy deficits during periods of high demand such as exercise or fasting. CPT2 deficiency is an autosomal recessive genetic disorder with several clinical forms, the most common being the adult-onset myopathic form characterized by muscle pain, weakness, exercise intolerance, and recurrent rhabdomyolysis.
Patients with this condition are typically advised to avoid high-fat meals, prolonged fasting, and intense physical activity. However, the precise mechanisms by which dietary fat alone influences muscle health in CPT2-deficient individuals have remained unclear until now. The study addresses this gap by examining chronic exposure to a high-fat diet in a controlled genetic model.
Study Design and Mouse Model Details
Researchers employed mice with skeletal muscle-specific deletion of the Cpt2 gene (Cpt2 Sk−/−), created using the human alpha-skeletal actin promoter to drive Cre recombinase expression. Control littermates without the Cre transgene served as comparisons. Animals received either standard chow or a high-fat diet providing 60 percent of calories from fat for up to eight weeks. Key assessments included muscle contractility measurements, mitochondrial respiratory capacity, transcriptional and protein analyses, and histopathological evaluation of muscle tissue.
The high-fat diet was selected to mimic scenarios of elevated lipid availability while isolating the effects of impaired long-chain fatty acid oxidation. Mice maintained normal food intake and showed resistance to diet-induced weight gain and adiposity, consistent with prior observations in this model, yet muscle-specific deficits emerged clearly.
Key Findings on Muscle Contractility and Force Production
After eight weeks, high-fat feeding significantly impaired ex vivo muscle force production in both glycolytic extensor digitorum longus (EDL) and oxidative soleus muscles of CPT2-deficient mice. This reduction in contractile performance highlights how dietary lipid overload can directly compromise muscle function when fatty acid oxidation is defective. Control mice did not exhibit comparable declines, underscoring the interaction between the genetic defect and dietary fat.
These functional deficits align with clinical reports of muscle weakness and exercise intolerance in patients, suggesting that even moderate or unavoidable increases in dietary fat may contribute to symptom flares beyond traditional triggers like fasting or stress.
Photo by julien Tromeur on Unsplash
Mitochondrial Dysfunction and Respiratory Capacity Changes
Mitochondrial bioenergetics were markedly affected. Despite evidence of increased mitochondrial biogenesis, respiratory capacity declined significantly in CPT2-deficient muscle under high-fat conditions. This paradox—more mitochondria yet poorer function—points to impaired quality or efficiency of the organelles when long-chain fatty acid substrates accumulate without proper oxidation.
The findings emphasize the importance of balanced substrate utilization in muscle mitochondria. When CPT2 is absent, excess lipids may lead to toxic intermediates or structural damage within the organelles, reducing their ability to generate ATP efficiently.
Structural Damage and Histopathological Changes
Histological analysis revealed pronounced structural deterioration in oxidative soleus muscle of high-fat-fed CPT2-deficient mice. Changes included reduced fiber size and the presence of ragged red fibers, classic markers of mitochondrial myopathy. Increased lipid and mitochondria accumulation within myofibers further indicated pathological remodeling driven by the combination of genetic deficiency and dietary fat.
Ragged red fibers reflect subsarcolemmal accumulation of abnormal mitochondria and are often seen in primary mitochondrial disorders. Their appearance here demonstrates how secondary dietary factors can intensify core myopathic features in fatty acid oxidation disorders.
Broader Implications for Patients and Clinical Management
The results offer a mechanistic explanation for why some individuals with CPT2 deficiency experience unexplained episodes of muscle breakdown even when avoiding obvious triggers. High-fat meals, which are sometimes difficult to eliminate entirely due to nutritional needs or dietary variety, may silently worsen underlying pathology over time.
Clinicians managing these patients may need to reinforce dietary counseling with greater emphasis on long-chain fat restriction while ensuring adequate alternative energy sources such as carbohydrates or medium-chain triglycerides. The study also raises questions about monitoring mitochondrial health and muscle integrity in at-risk populations through non-invasive methods.
Context Within Ongoing Metabolic Disease Research
This publication builds on earlier work from the same research groups examining CPT2 deficiency in cardiac and skeletal muscle contexts. Previous studies have shown that muscle-specific CPT2 loss leads to oxidative weakness and exercise intolerance even without dietary challenge, yet the animals resist obesity and insulin resistance on high-fat diets. The current findings resolve part of this paradox by revealing hidden muscle costs of lipid overload.
Similar principles may apply to other fatty acid oxidation disorders, where dietary management remains a cornerstone of care. Understanding fiber-type specific responses—glycolytic versus oxidative muscles—could guide more personalized interventions in the future.
Photo by julien Tromeur on Unsplash
Future Research Directions and Therapeutic Opportunities
Further investigations could explore dose-response relationships with varying fat percentages, the role of specific fatty acid types such as omega-3 or saturated fats, and potential interventions like mitochondrial-targeted antioxidants or exercise protocols adapted for metabolic limitations. Human studies translating these mouse findings would be valuable, though ethical and practical constraints limit direct dietary challenges in patients.
Advances in gene therapy or pharmacological chaperones for CPT2 could eventually complement dietary strategies. In the interim, this research strengthens the rationale for proactive nutritional guidance in fatty acid oxidation disorder clinics worldwide.
Relevance to Academic and Biomedical Research Communities
For researchers in metabolism, muscle physiology, and rare genetic diseases, the study exemplifies rigorous use of conditional knockout models to dissect complex gene-environment interactions. It highlights the value of multi-modal assessments combining physiology, bioenergetics, and histology. Academic institutions with strong programs in mitochondrial biology or metabolic genetics may find this work particularly relevant for training the next generation of investigators.
The publication also underscores ongoing needs for interdisciplinary collaboration between basic scientists and clinicians to translate mechanistic discoveries into improved patient outcomes.